Anti‐Mi‐2 antibody‐positive inflammatory myopathy during treatment with golimumab. Issue 5 (19th June 2018)

• Record Type: Journal Article
• Authors: Hirunagi, Tomoki; Goto, Yoji; Mano, Kazuo
• Is Part Of: Neurology and clinical neuroscience. Volume 6:Issue 5(2018:Sep.)
• Page Start: 131
• Page End: 132
• Publication Date: 2018-06-19
• Subjects: anti‐Mi‐2 antibody -- golimumab -- inflammatory myopathy -- TNF‐alpha inhibitor; Neurology -- Periodicals; Neurosciences -- Periodicals; 616.8
• DOI: 10.1111/ncn3.12202
• Languages: English
• ISSNs: 2049-4173

Abstract

Abstract: A 56‐year‐old woman, who was treated with golimumab for rheumatoid arthritis, presented with myalgia and rash. She had proximal limbs weakness, and erythematous papules were evident on her hands and face. Her serum creatine kinase levels were elevated, and anti‐Mi‐2 antibody was detected. Magnetic resonance imaging of muscles revealed inflammatory lesions in muscles and soft tissues. She was diagnosed with inflammatory myopathy. A drug‐induced mechanism was suspected; therefore, we stopped treating her with golimumab and instead treated her with prednisolone. Subsequently, her symptoms gradually improved. This case suggests that tumor necrosis factor‐alpha inhibitors may induce anti‐Mi‐2 antibody‐positive inflammatory myopathies.